Gapping up
In reaction to earnings/guidance:
In reaction to earnings/guidance:
- CDLX +47.8%, DESP +11.2%, WW +6.4%, GRPN +4.6%, AGRO +4.1%, GETY +3.9%, PHR +3.8%, BKE +3.6%, WPM +1.9%, RDUS +1.8%
Other news:
- GERN +80% (resumes trading after being halted on Thurs; FDA Advisory Committee voted in favor of the clinical benefit/risk profile of Imetelstat)
- MDGL +25.2% (confirms FDA approval of Rezdiffra)
- ISRG +3.7% (FDA provides 510(k) clearance for da Vinci 5)
- VOD +3.7% (announces reshaped European footprint €8 bln sale of Vodafone Italy & €4 bln capital return)
- SOPH +3.3% (SOPHiA GENETICS and The French Kidney Cancer Research Network (UroCCR) Publish Results from Multiyear Collaboration)
- ACIU +3% (files $350 mln mixed shelf securities offering)
- LAW +2.9% (authorizes new $20 mln share repurchase program)
- GEO +2.8% (Executive Chairman insider buy disclosure - bought 50000 shares at $12.465 - $12.50 worth approx. $624K)
- HITI +2.4% (will acquire all IP including trademarks and other assets of the Queen of Bud brand)
- THR +2.4% (authorized the repurchase of up to $50 million of Thermon's outstanding shares of common stock)
- SWI +2.1% (declared a special cash dividend on the company's common stock of $1.00/share)
- TRP +2% (to sell Prince Rupert Gas Transmission entities)
- AJG +1.7% (may sell up to 3 mln shares in ATM offerings)
- AQST +1.5% (data from pivotal study for Anaphylm)
- BGNE +1.3% (FDA approves TEVIMBRA)
- HRTG +1.1% (files $100 mln mixed shelf securities offering) TRIN +1% (increases dividend)